Clinical Trials Browser

Phase 2 × Hematologic Diseases × Sirolimus × Clear all

NCT03246906 2026-05-14

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematologic Diseases, Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT00350181 2021-09-23

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 2 Completed

11 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoma, Non-Hodgkin

NCT01220297 2017-06-05

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 2 Terminated

3 enrolled 13 charts

LymphoidOther hematologic neoplasm

Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin